Allspring Global Investments Holdings LLC Decreases Stock Holdings in Voyager Therapeutics, Inc. $VYGR

Allspring Global Investments Holdings LLC lowered its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 5.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 56,910 shares of the company’s stock after selling 3,552 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.10% of Voyager Therapeutics worth $177,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Armistice Capital LLC grew its position in Voyager Therapeutics by 0.7% in the 1st quarter. Armistice Capital LLC now owns 5,436,000 shares of the company’s stock valued at $18,374,000 after acquiring an additional 40,000 shares during the last quarter. Vestal Point Capital LP grew its position in Voyager Therapeutics by 1.6% in the 1st quarter. Vestal Point Capital LP now owns 1,249,418 shares of the company’s stock valued at $4,223,000 after acquiring an additional 19,418 shares during the last quarter. Erste Asset Management GmbH grew its position in Voyager Therapeutics by 5.5% in the 1st quarter. Erste Asset Management GmbH now owns 1,116,793 shares of the company’s stock valued at $3,826,000 after acquiring an additional 58,415 shares during the last quarter. AQR Capital Management LLC lifted its stake in Voyager Therapeutics by 179.3% in the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock worth $1,674,000 after acquiring an additional 317,927 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in Voyager Therapeutics by 863.3% in the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock worth $778,000 after acquiring an additional 206,758 shares during the period. Institutional investors own 48.03% of the company’s stock.

Insider Transactions at Voyager Therapeutics

In related news, CFO Nathan D. Jorgensen sold 7,666 shares of the stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $4.78, for a total transaction of $36,643.48. Following the transaction, the chief financial officer owned 123,834 shares of the company’s stock, valued at approximately $591,926.52. This represents a 5.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.53% of the company’s stock.

Voyager Therapeutics Stock Performance

Shares of VYGR stock opened at $4.65 on Monday. The stock’s fifty day moving average is $4.30 and its two-hundred day moving average is $3.62. The firm has a market capitalization of $257.94 million, a P/E ratio of -2.51 and a beta of 0.95. Voyager Therapeutics, Inc. has a fifty-two week low of $2.64 and a fifty-two week high of $7.44.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). The business had revenue of $5.20 million for the quarter, compared to analyst estimates of $9.50 million. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. On average, equities analysts forecast that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

VYGR has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Voyager Therapeutics in a research report on Friday. Wedbush decreased their price objective on shares of Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Monday, September 15th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.96.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.